ALK and non-small cell lung carcinoma: Recently, second-generation TKI alectinib has shown to delay the development of brain metastases compared to first-generation TKI and also demonstrated promising efficacy in the CNS for crizotinib-resistant ALK-positive NSCLC patients (73, 74).